Development
Eli Lilly and Company
LLY
$765.68
-$0.16-0.02%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 34.12B | 32.07B | 29.52B | 27.69B | 28.54B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.12B | 32.07B | 29.52B | 27.69B | 28.54B |
| Cost of Revenue | 7.08B | 6.84B | 6.56B | 6.18B | 6.63B |
| Gross Profit | 27.04B | 25.23B | 22.95B | 21.51B | 21.91B |
| SG&A Expenses | 6.94B | 6.68B | 6.52B | 6.24B | 6.07B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.34B | 22.27B | 21.22B | 19.99B | 19.89B |
| Operating Income | 10.79B | 9.80B | 8.30B | 7.70B | 8.65B |
| Income Before Tax | 6.55B | 6.14B | 7.28B | 6.28B | 6.81B |
| Income Tax Expenses | 1.31B | 1.15B | 783.00M | 595.70M | 561.60M |
| Earnings from Continuing Operations | 5.24K | 4.99K | 6.50K | 5.69K | 6.24K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.24B | 4.99B | 6.50B | 5.69B | 6.24B |
| EBIT | 10.79B | 9.80B | 8.30B | 7.70B | 8.65B |
| EBITDA | 12.31B | 11.32B | 9.77B | 9.15B | 10.18B |
| EPS Basic | 5.81 | 5.53 | 7.21 | 6.30 | 6.92 |
| Normalized Basic EPS | 7.24 | 6.58 | 5.53 | 5.11 | 5.80 |
| EPS Diluted | 5.80 | 5.52 | 7.19 | 6.29 | 6.90 |
| Normalized Diluted EPS | 7.23 | 6.57 | 5.52 | 5.10 | 5.78 |
| Average Basic Shares Outstanding | 3.60B | 3.61B | 3.61B | 3.61B | 3.61B |
| Average Diluted Shares Outstanding | 3.61B | 3.61B | 3.61B | 3.61B | 3.62B |
| Dividend Per Share | 4.52 | 4.37 | 4.22 | 4.07 | 3.92 |
| Payout Ratio | 77.65% | 78.90% | 58.51% | 64.49% | 56.62% |